[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353876-105":59,"doc-detail-353876-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","a-randomized-phase-iii-clinical-trial-of-weekly-versus-tri-weekly-cisplatin-based-chemoradiotherapy-for-locally-advanced-cervical-cancer-results-of-the-taco-study","A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer - results of the TACO (GCIG/KGOG 1027/THAI 2012) study","","Locally advanced cervical cancer is treated with cisplatin-based chemoradiotherapy, yet the optimal cisplatin dose and schedule remains uncertain. This prospective, randomized phase III trial compared weekly cisplatin 40 mg/m2 for six cycles with tri-weekly cisplatin 75 mg/m2 for three cycles during radiotherapy in 314 patients (stage IIB-IVA). Weekly dosing caused more chemotherapy delay, while tri-weekly dosing reduced grade 3–4 hematologic toxicity and improved quality of life. Tri-weekly treatment was not superior for 3-year recurrence-free survival.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-randomized-phase-iii-clinical-trial-of-weekly-versus-tri-weekly-cisplatin-based-chemoradiotherapy-for-locally-advanced-cervical-cancer-results-of-the-taco-study/353876/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-randomized-phase-iii-clinical-trial-of-weekly-versus-tri-weekly-cisplatin-based-chemoradiotherapy-for-locally-advanced-cervical-cancer-results-of-the-taco-study/353876.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment schedules were compared in the trial?","Question",{"text":113,"@type":114},"Patients were randomized to receive either weekly cisplatin 40 mg/m2 (six cycles) or tri-weekly cisplatin 75 mg/m2 (three cycles) concurrently with radiotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What were the primary and key secondary outcomes?",{"text":118,"@type":114},"The primary endpoint was 3-year recurrence-free survival under a superiority design. Overall survival, toxicity profiles, and quality of life were also analyzed.",{"name":120,"@type":111,"acceptedAnswer":121},"Did tri-weekly cisplatin improve survival compared with weekly dosing?",{"text":122,"@type":114},"No. The 3-year recurrence-free survival rates did not differ significantly between the two arms.",{"name":124,"@type":111,"acceptedAnswer":125},"How did the toxicity and quality of life compare between the arms?",{"text":126,"@type":114},"The tri-weekly arm had less grade 3–4 hematologic toxicity and better quality of life scores across several domains than the weekly arm.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},353876,1790463018,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ORIGINAL ARTICLE  \nA randomized phase III clinical trial of weekly versus tri-weekly  \ncisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study  \nS. Y. Ryu1 ∗, B. H. Nam2, M. H. Kim1, W. I. Jang3, C. Sitathanee4, T. D. Linh5, K. H. Lee6, W. M. Lee7, E. T. Kim8, S. B. Kang9, J. H. Kim10, J. Y. Park11, K. B. Lee12, C. H. Cho13, H. Lou14, Y. H. Kim15, Y. T. Kim16, Y. H. Lee17, X. Wu18, J. W. Kim19, S. I. Park20, S. Jeon21, D. H. Thinh5, S. F. Kry22, D. Gaffney23, W. Small24 & S. Wilailak25 ∗  \n1Department of Gynecologic Oncology, Korea Institute of Radiological & Medical Science, Seoul; 2Data Management Center, Korea Gynecologic Oncology Group, Seoul; 3Department of Radiation Oncology, Korea Institute of Radiological & Medical Science, Seoul, Republic of Korea; 4Department of Radiation Oncology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 5Department of Radiation Oncology, Ho Chi Minh City Oncology Hospital, Ho Chi Minh, Vietnam; 6Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, Catholic University, Seoul; 7Department of Obstetrics and Gynecology, Hanyang University, Seoul; 8Department of Obstetrics and Gynecology, Kosin University Gospel Hospital, Busan; 9Department of Obstetrics and Gynecology, Hosan Women’s Hospital, Seoul; 10Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University, Seoul; 11Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 12Department of Obstetrics and Gynecology, Gachon University Gil Hospital, Incheon; 13Department of Obstetrics and Gynecology, Keimyung University, Daegu, Republic of Korea; 14Department of Obstetrics and Gynecology, Zheijiang Cancer Center, Hangzhou, China; 15Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul; 16Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul; 17Department of Obstetrics and Gynecology, Kyungpook National University College of Medicine, Daegu, Republic of Korea; 18Department of Gynecologic Oncology, Fudan University Cancer Institute, Shanghai, China; 19Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul; 20Department of Obstetrics and Gynecology, Dongnam Institute of Radiological & Medical Science, Busan; 21Department of Obstetrics and Gynecology, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea; 22Department of Radiation Physics, IROC Houston QA Center, University of Texas MD Anderson Cancer Center, Houston; 23Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City; 24Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, USA; 25Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand  \nAvailable online xxx  \nBackground: The standard treatment for locally advanced cervical cancer is cisplatin-based chemoradiotherapy; however, the optimal dose and dosing schedule of cisplatin remain debated. The aim of this study was to compare the clinical outcomes of weekly cisplatin at 40 mg/m2 versus those of tri-weekly cisplatin at 75 mg/m2 during radiation in patients with locally advanced cervical cancer.  \nPatients and methods: In this prospective, randomized clinical trial, we enrolled 314 patients with stage IIB-IVA cervical cancer, randomly assigning them in a 1 : 1 ratio into two arms. The weekly arm received a weekly dose of 40 mg/m2 cisplatin for six cycles, whereas the tri-weekly arm received a tri-weekly dose of 75 mg/m2 cisplatin for three cycles, both concurrently with radiotherapy. The primary endpoints included 3-year recurrence-free survival according to a superiority design, with P \u003C 0.05 indicative of statistical significance. Overall survival, toxicity profiles, and quality","cbCaimfN2VqcsxgV","https://ap.wps.com/l/cbCaimfN2VqcsxgV","pdf",700631,"English","# Background\n# Patients and methods\n# Results\n# Conclusion","[{\"question\":\"What treatment schedules were compared in the trial?\",\"answer\":\"Patients were randomized to receive either weekly cisplatin 40 mg/m2 (six cycles) or tri-weekly cisplatin 75 mg/m2 (three cycles) concurrently with radiotherapy.\"},{\"question\":\"What were the primary and key secondary outcomes?\",\"answer\":\"The primary endpoint was 3-year recurrence-free survival under a superiority design. Overall survival, toxicity profiles, and quality of life were also analyzed.\"},{\"question\":\"Did tri-weekly cisplatin improve survival compared with weekly dosing?\",\"answer\":\"No. The 3-year recurrence-free survival rates did not differ significantly between the two arms.\"},{\"question\":\"How did the toxicity and quality of life compare between the arms?\",\"answer\":\"The tri-weekly arm had less grade 3–4 hematologic toxicity and better quality of life scores across several domains than the weekly arm.\"}]","A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer - results of the TACO (GCIG/KGOG 1027/THAI 2012) study | PDF",1790107687,18,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bea0d5c10613f1640a5137433857dbe.webp",983,1269,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e504a7a3068fc2341a6e1e8bf6ce526a.webp",982,1268,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2850a2cb530f946539d0402626c9c0e2.webp",981,1266,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c9b99452178463d6b41ba47c0c27858.webp",980,1265]